Maintaining Lower Levels of Care Through Automated Perineal Hygiene
Primary Purpose
Incontinence, Dermatitis
Status
Unknown status
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Wellness toilet system
Sponsored by
About this trial
This is an interventional treatment trial for Incontinence
Eligibility Criteria
Inclusion Criteria:
- Limitation of Activity of Daily Living - Toileting, requiring assistance, beginning stages of unmanaged incontinence. For the purposes of this study, toileting refers to maintenance of hygiene and ability to clean the perineum after urination or defecation. It does not include inability to transfer to a commode only.
Exclusion Criteria:
- Inability to obtain consent
- Weight over 300 pounds
- Prior pelvic radiation
- Pelvic Floor surgery within the 6 weeks prior to enrollment
- Active perineal infection
- Active chemotherapy
Sites / Locations
- The CanterburyRecruiting
- The Village at MarymountRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Wellness toileting system
Arm Description
Subjects given SchwabCare Wellness Toileting system
Outcomes
Primary Outcome Measures
Days Remaining in independent living environment
Subject does not require assistance for perineal hygiene that requires change of living environment
Secondary Outcome Measures
Improved quality of life
Subject using device will experience improved quality of life derived from the quality of life in incontinence scale
Treatment and prevention of incontinence associated dermatitis
Device will treat existing, and prevent dermatitis in subjects with incontinence, evaluated using the Kennedy Scale
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT03051321
Brief Title
Maintaining Lower Levels of Care Through Automated Perineal Hygiene
Official Title
Maintaining Lower Levels of Care Through Automated Perineal Hygiene
Study Type
Interventional
2. Study Status
Record Verification Date
May 2018
Overall Recruitment Status
Unknown status
Study Start Date
April 1, 2017 (Actual)
Primary Completion Date
June 2018 (Anticipated)
Study Completion Date
October 2018 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
SchwabCare
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The inability to independently manage perineal hygiene after toileting is a common issue for those in assisted living and nursing home environments. It is associated with skin breakdown (dermatitis), increased nursing costs, and loss of patient self-esteem and independence. Water-based toileting has been evaluated as a possible adjunct to patient care, but its uptake has been limited by ineffective cleansing and drying.
40 subjects with limitations in independent capacity for perineal hygiene that require assistance with toileting will be recruited from a continued care retirement center. Subjects will be assessed for incontinence, and skin breakdown or irritation. Subjects will be provided a Wellness Toilet System, cleanser, and, if needed, zinc oxide barrier spray to be applied in cases of dermatitis.
Investigators hypothesize that subjects given the device will remain more independent, with higher quality of life. Secondary hypotheses are that subjects will experience improved relationships with their caregivers, and that active dermatitis will be treated in those already with the condition, and prevented in those at risk.
Detailed Description
The prevalence of incontinence and inability to maintain personal perineal hygiene increases with higher levels of nursing care. While more than 75% of those in assisted living and home care settings are able to independently care for themselves after toileting, up to 75% of nursing home residents have regular episodes of urinary or fecal incontinence and require aid with toileting. This implies that whereas incontinence is a primary diagnosis in only 10% of nursing home admissions, it represents a major contributor to morbidity among all nursing home residents, and with that, an important target for efforts at cost containment. Inadequate independent perineal hygiene and dependence on caregivers for effective toileting raises global costs and adversely affects well-being for those in assisted living and dependent living environments. It is also associated with an increase in incontinence and incontinence associated dermatitis, which carries higher risks of urinary tract infection and skin infection. Finally, in many institutions, loss of toileting independence mandates a shift to a higher intensity environment, and with that incurs significant cost.
Water-based toileting has been evaluated as a potential intervention for nursing home residents with impaired toileting capacity. In that study, while investigators found significant overall improvement those using the device, less than half were neither effectively cleaned nor dry at the end of use. Because of this limited reliability, currently available devices are not thought to offer enough significant advantages for routine use in nursing home settings.
Incontinence and incontinence associated dermatitis (IAD) is common among residents with impaired perineal hygiene and toileting. Adherence to prescribed medications and therapies directed at the perineum is a major barrier to regular use among those with fecal or urinary incontinence. Difficulty in accessing the perineum make adherence challenging to those with both full and limited mobility, often requiring assistance from a caregiver. The associated loss of independence and dignity are major detriments to quality of life. Novel formulations of zinc oxide, using aerosol based spray application, facilitate use and improve patient acceptance. In a 2014 nursing home based industry study, spray based zinc oxide was preferred by 80% of patients and caregivers, and improved treatment and prevention of IAD in 70% of the study participants.
Adequate cleansing and drying prior to the application of barrier products is key to effective prevention of skin breakdown. Water-based cleaning of the perineum after toileting has been demonstrated to improve hygiene over standard mechanical, paper-based cleansing, especially in those with limited mobility or incontinence. Evidence further demonstrates that the addition of pH balanced cleansers, applied without mechanical abrasion from cloths or wipes, advances hygiene and minimizes risk of secondary infection.
Study Aims
The aims of this study are to evaluate whether an automated delivery system for cleansing the perineum can keep subjects who would normally move to higher levels of assistance at lower levels of nursing care. A secondary aim will be to evaluate whether an automated hands-free application of zinc oxide barrier spray effectively treats and prevents incontinence associated dermatitis in a population with active or recurrent IAD. Finally, the study aims to demonstrate cost savings through a cost effectiveness analysis.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Incontinence, Dermatitis
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
40 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Wellness toileting system
Arm Type
Experimental
Arm Description
Subjects given SchwabCare Wellness Toileting system
Intervention Type
Device
Intervention Name(s)
Wellness toilet system
Other Intervention Name(s)
SchwabCare Wellness Toileting System
Intervention Description
Water-based toileting with capacity to apply zinc oxide barrier spray to treat incontinence associated dermatitis
Primary Outcome Measure Information:
Title
Days Remaining in independent living environment
Description
Subject does not require assistance for perineal hygiene that requires change of living environment
Time Frame
24 weeks
Secondary Outcome Measure Information:
Title
Improved quality of life
Description
Subject using device will experience improved quality of life derived from the quality of life in incontinence scale
Time Frame
24 weeks
Title
Treatment and prevention of incontinence associated dermatitis
Description
Device will treat existing, and prevent dermatitis in subjects with incontinence, evaluated using the Kennedy Scale
Time Frame
24 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
- Limitation of Activity of Daily Living - Toileting, requiring assistance, beginning stages of unmanaged incontinence. For the purposes of this study, toileting refers to maintenance of hygiene and ability to clean the perineum after urination or defecation. It does not include inability to transfer to a commode only.
Exclusion Criteria:
Inability to obtain consent
Weight over 300 pounds
Prior pelvic radiation
Pelvic Floor surgery within the 6 weeks prior to enrollment
Active perineal infection
Active chemotherapy
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jacqueline Silvia
Phone
(855) 239-2106
Email
jsilvia@schwabcare.com
First Name & Middle Initial & Last Name or Official Title & Degree
Richard s Tilson, MD MPH
Phone
(978) 459-6737
Email
mtilson2@lowellgi.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Richard S Tilson, MD MPH
Organizational Affiliation
Director of Clinical Investigation
Official's Role
Principal Investigator
Facility Information:
Facility Name
The Canterbury
City
Rancho Palos Verdes
State/Province
California
ZIP/Postal Code
90275
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jacqualine Silvia
Facility Name
The Village at Marymount
City
Garfield Heights
State/Province
Ohio
ZIP/Postal Code
44125
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jacqueline Silvia
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Maintaining Lower Levels of Care Through Automated Perineal Hygiene
We'll reach out to this number within 24 hrs